1. Introduction {#sec1}
===============

The incidence and prevalence of diabetes mellitus are dramatically increasing worldwide \[[@B1]\]. Epidemiological research shows that diabetic patients have a higher risk of cardiovascular diseases \[[@B2]\]. The main cause of morbidity and mortality in diabetic patients is cardiovascular diseases.

Glucagon-like peptide-1 (GLP-1) is produced in gut L-cells. It contains 30 amino acids. The main physiological function of GLP-1 is stimulation of insulin secretion from pancreatic *β* cells when glucose is orally taken up in the human body. GLP-1 can also inhibit glucose production and appetite, activate adipose and muscle glucose uptake and storage, and thus moderate insulin sensitivity. However, GLP-1 is quickly hydrolyzed by dipeptidyl peptidase-4 (DPP-4).

DPP-4 inhibitors are a new class of GLP-1 based antidiabetic drugs. As one type of DPP-4 inhibitors, vildagliptin controls blood glucose by inhibiting the enzymatic activity of DPP-4. DPP-4 is also found on endothelial cells in the cardiovascular system, and increasing research has focused on the benefit of DPP-4 inhibitors on cardiovascular function. Sitagliptin (one type of DPP-4 inhibitor) has been proven to significantly attenuate heart failure-related left ventricular (LV) end-diastolic pressure, systolic performance, and chamber stiffness in an ablation-induced cardiac dysfunction rat model \[[@B3]\]. In a clinical trial, sitagliptin enhanced global and regional LV function in type 2 diabetes mellitus (T2DM) patients with coronary artery \[[@B4]\]. Vildagliptin exerts cardioprotective effects in obesity-based insulin resistance \[[@B5], [@B6]\], myocardial infarction (MI) \[[@B7]\], and ischemia-reperfusion (I/R) injury rat models \[[@B8]\]. However, the exact mechanism of the beneficial effect of vildagliptin on the aorta in diabetic rats remains to be elucidated.

In this study, we hypothesized that vildagliptin improved aorta function through multiple pathways. We employed a whole genomic expression array and bioinformatics method to explore the pathway involved in aorta vascular function moderation in diabetic rats.

2. Materials and Methods {#sec2}
========================

2.1. Animal Treatments and Diets {#sec2.1}
--------------------------------

Five-week-old male Sprague-Dawley rats were obtained from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, and Peking Union Medical College (Beijing, China, SCXK-2014-0013). The animal protocol was approved by the Animal Care Committee of the Peking Union Medical Hospital Animal Ethics Committee (Project XHDW-2015-0051, 15 Feb 2015), and all efforts were made to minimize suffering. All the rats were fed in a light/dark cycle (12 hours : 12 hours) environment and were free to drink water. Three days after arrival, rats were randomly divided into four groups (*n* = 6 per group): normal control group, diabetic group, low-dose vildagliptin (vil-low), and high-dose vildagliptin (vil-high). The normal control group was fed a standard rodent diet (kcal%: 10% fat, 20% protein, and 70% carbohydrate; 3.85 kcal/gm). Other groups were fed a high-fat diet (kcal%: 45% fat, 20% protein, and 35% carbohydrate; 4.73 kcal/gm, Research Diet, New Brunswick, NJ, USA). After 4 weeks, diabetic, low-dose vildagliptin, and high-dose vildagliptin groups were given a single injection of streptozotocin (STZ, 30 mg/kg body weight, i.p., Sigma-Aldrich, St. Louis, MO, USA). Fasting blood glucose \> 11.1 mmol/L was the standard for the diabetic model. Then, vil-low and vil-high groups were treated with 10 mg or 20 mg vildagliptin (Novartis Pharma AG, Basel, Switzerland)/kg of body weight by daily gavage for 12 weeks. Normal control and diabetic groups were given normal saline. After 12 weeks of treatment, the rats were anesthetized using ketamine (100 mg/kg i.p., Pharmacia and Upjohn Ltd., Crawley, UK), followed by withdrawal of food overnight. Blood samples were obtained from the abdominal aorta. Then, the rats were sacrificed by decapitation. The thoracic aorta was quickly removed. Some aortas were placed in Krebs solution (120 mmol/L of NaCl, 4.7 mmol/L of KCl, 1.18 mmol/L of KH~2~PO~4~, 2.25 mmol/L of CaCl~2~, 24.5 mmol/L of NaHCO~3~, 1.2 mmol/L of MgSO~4~·7H~2~O, 11.1 mmol/L of glucose, and 0.03 mmol/L of EDTA) and aerated with 95% O~2~ and 5% CO~2~. Other aortas were frozen in liquid nitrogen and stored at −80°C for a gene microarray experiment.

2.2. Body Weight and Fasting Blood Glucose Measurements {#sec2.2}
-------------------------------------------------------

The rats were weighed every 4 weeks. Fasting blood glucose levels were measured by Bayer Contour TS glucometer (Hamburg, Germany).

2.3. Oral Glucose Tolerance Test (OGTT) {#sec2.3}
---------------------------------------

An OGTT was performed after 12 weeks of treatment. Blood glucose levels were measured at 30, 60, and 120 min after an oral administration of 20% glucose at a dose of 2 g/kg. The area under the curve (AUC) was calculated by the linear trapezoid method \[[@B9]\].

2.4. Serum Insulin and Lipid Panel Measurements {#sec2.4}
-----------------------------------------------

Serum fasting insulin was analyzed using an ELISA kit (Millipore, Billerica, MA, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by the following formula: FBG (mmol/L) × fasting insulin (*μ*IU/mL)/22.5. Serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured using an enzyme end-point kit (Roche Diagnostics GmbH, Mannheim, Germany).

2.5. Isometric Contractile Tension Assay {#sec2.5}
----------------------------------------

Isometric contractile tension was determined as follows and described previously \[[@B10]\]. The aortic ring segments (3 mm width) were incubated with Krebs solution (120 mmol/L of NaCl, 4.7 mmol/L of KCl, 1.18 mmol/L of KH~2~PO~4~, 2.25 mmol/L of CaCl~2~, 24.5 mmol/L of NaHCO~3~, 1.2 mmol/L of MgSO~4~·7H~2~O, 11.1 mmol/L of glucose, and 0.03 mmol/L of EDTA), aerated with 95% O~2~ and 5% CO~2~, and then preconstricted with phenylephrine (Phe, 10^−7^ mmol/L). Isometric contractile tension was measured by a BL-410 Biological function system (Chengdu Tai Meng Science and Technology Co., Ltd., Chengdu, China). Once a basal contraction was obtained, 10^−10^ to 10^−4^ mol/L of acetylcholine (Ach) was cumulatively added to the solution.

2.6. RNA Extraction, Amplification, Labeling, and Hybridization {#sec2.6}
---------------------------------------------------------------

To look for the differentially expressed genes under vildagliptin treatment in diabetic rats, we performed gene whole transcript-based array in vil-high group and diabetic group (*n* = 3 in each group). Total RNA was extracted from aortas using a mirVana™ RNA Isolation Kit (Ambion, San Paulo, SP, Brazil). The RNA was purified using an RNeasy Kit (Qiagen, Hilden, Germany), quantified by NanoDrop ND-2000 spectrophotometry (Nanodrop Tech, Rockland, Del, Wilmington, DE, USA), and qualified by agarose gel electrophoresis. Total RNA (100 ng) was used for cDNA synthesis. cRNA was synthesized followed by two-strand cDNA. Biotin-labeled cRNA was hybridized to an Affymetrix GeneChip Rat Gene 2.0 ST whole transcript-based array (Affymetrix Technologies, Santa Clara, CA, USA). After hybridization, the microarrays were washed, stained, and scanned with an Affymetrix Scanner 3000 7G (Santa Clara, CA, USA).

The microarray signals were analyzed using Expression Console software (version 1.4.1, Affymetrix, Santa Clara, CA, USA). The significance of the difference in genes was determined by one-way ANOVA. Differentially expressed genes were defined as genes with a fold change \> 2.0 and *P* \< 0.05. The microarray raw data were submitted to the Gene Expression Omnibus (GEO) repository (GSE102196).

2.7. Bioinformatics Analysis for Microarray {#sec2.7}
-------------------------------------------

DAVID (Database for Annotation, Visualization and Integrated Discovery) software (<https://david.abcc.ncifcrf.gov/>) \[[@B11]\] was used to perform gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The Search Tool for the Retrieval of Interacting Genes (STRING) database (<https://string-db.org/>) \[[@B12]\] was used to analyze the interaction network for differentially expressed genes.

2.8. Validation of Differentially Expressed Genes by Quantitative PCR {#sec2.8}
---------------------------------------------------------------------

The expression levels of three differentially expressed genes were measured by qPCR to validate the results of the microarray. All primers are listed in [Table 1](#tab1){ref-type="table"}.*Actin* was used as an internal control.

2.9. Statistical Analyses {#sec2.9}
-------------------------

Data are presented as the means ± standard deviation (SD). One-way ANOVA analysis followed by Student\'s *t*-test was used to compare differences among groups. *P* \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Vildagliptin Moderated Blood Glucose and Insulin Resistance {#sec3.1}
----------------------------------------------------------------

After 12 weeks of treatment, vildagliptin significantly reduced fasting blood glucose AUC in OGTT (*P* \< 0.05, Figures [1(b)](#fig1){ref-type="fig"} and [1(f)](#fig1){ref-type="fig"}). Additionally, fasting serum insulin and HOMA-IR index in the vildagliptin-treated group were lower than in the diabetic group (*P* \< 0.05, Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}).

3.2. Vildagliptin Decreased Blood Lipid Levels {#sec3.2}
----------------------------------------------

Vildagliptin decreased TC and LDL-C levels in diabetic rats (*P* \< 0.01, Figures [1(g)](#fig1){ref-type="fig"} and [1(j)](#fig1){ref-type="fig"}).

3.3. Vildagliptin Depressed Vasorelaxation Responses of Aortic Rings to Ach {#sec3.3}
---------------------------------------------------------------------------

As shown in [Figure 1(k)](#fig1){ref-type="fig"}, endothelium-dependent vasodilation was impaired in diabetic rats compared with normal rats. Treatment with vildagliptin ameliorated this impairment (*P* \< 0.01).

3.4. Identification of Differentially Expressed Genes {#sec3.4}
-----------------------------------------------------

After filtering genes that had a cutoff of a 1.5-fold change or greater, we found that 150 genes were upregulated and 120 genes were downregulated in the vil-high group compared with the diabetic group (*P* \< 0.05).

3.5. GO Term Enrichment Analysis of Differentially Expressed Genes {#sec3.5}
------------------------------------------------------------------

In general, 91 GO terms were significantly enriched (*P* \< 0.05, [Table 2](#tab2){ref-type="table"}). The top 20 most significant biological process (BP) terms are shown in [Figure 2](#fig2){ref-type="fig"} (*P* \< 0.01). They were negative regulation of endopeptidase activity, epoxygenase P450 pathway, acute-phase response, blood coagulation, oxidation-reduction processes, cytoskeleton organization, negative regulation of fibrinolysis, microtubule-based processes, phosphatidylcholine metabolic processes, fibrinolysis, organ regeneration, complement activation classical pathway, inflammatory response, positive regulation of lipid catabolic process, triglyceride homeostasis, aging, cellular response to interferon gamma, cholesterol metabolic process, cholesterol homeostasis, and tissue regeneration.

3.6. Pathway Enrichment Analysis of Differentially Expressed Genes {#sec3.6}
------------------------------------------------------------------

In the pathway enrichment analysis, 12 pathway terms were significantly enriched (*P* \< 0.05, [Table 3](#tab3){ref-type="table"}). The top 10 most significant pathway terms were complement and coagulation cascades, retinol metabolism, steroid hormone biosynthesis, chemical carcinogenesis, linoleic acid metabolism, inflammatory mediator regulation of TRP channels, Gap junction, prion diseases, metabolic pathways, and arachidonic acid metabolism.

3.7. Gene Interaction Network {#sec3.7}
-----------------------------

Based on 270 differentially expressed genes, a gene interaction network was analyzed by the String software. We found that 257 nodes and 338 edges were constructed ([Figure 3](#fig3){ref-type="fig"}). Twenty-five genes had more than 5 edges. The top 10 genes by degree are listed in [Table 4](#tab4){ref-type="table"}.

3.8. Confirmation with qPCR {#sec3.8}
---------------------------

From the gene expression array results, we found that*Pon1* and*Bhmt* were in "metabolic pathway" (KEGG ID: rno01100), and*Angptl3* and*Pon1* were in several GO terms such as "positive regulation of lipid catabolic process" (GO: 0050996), "triglyceride homeostasis" (GO: 0070328), "cholesterol metabolic process" (GO: 0008203), "cholesterol homeostasis" (GO: 0042632), "response to hypoxia" (GO: 0001666), and "acylglycerol homeostasis" (GO: 0055090). So, we focused on these three genes in further study. As shown in [Figure 4](#fig4){ref-type="fig"}, the relative mRNA levels of angiopoietin-like 3*(Angptl3)* and betaine-homocysteine S-methyltransferase*(Bhmt)* in diabetic rats were significantly higher than those of normal rats (*P* \< 0.01), whereas the expression of these two genes was significantly reduced in vildagliptin-treated groups compared with those in diabetic rats (*P* \< 0.01). Conversely, paraoxonase 1*(Pon1)* decreased in the diabetic group. However, Pon1 increased in vildagliptin-treated rats (*P* \< 0.01). These results were consistent with the microarray results.

4. Discussion {#sec4}
=============

In our study, we found that vildagliptin reduced blood glucose, TC, and LDL-C. In a clinical trial, sitagliptin-combined metformin add-on therapy led to greater improvement in HbA1c than the metformin monotherapy group after 18 weeks of treatment. Moreover, sitagliptin combined with metformin significantly reduced TG, TC, and LDL-C and increased HDL-C compared with the metformin group \[[@B13]\].

We used aortic rings to test the Ach-induced endothelium-dependent vasodilation. In diabetic rats, Ach-induced endothelium-dependent vasodilation was impaired. Vildagliptin augmented endothelial function. Other DDP-4 inhibitors also had similar vasoprotective effects. Saxagliptin treatment for 8 weeks increased aortic nitric oxide (NO) release by 22% and reduced mean arterial pressure in spontaneously hypertensive rats \[[@B14]\]. Moreover, sitagliptin treatment for 2 weeks protected endothelial function and reduced systolic blood pressure in spontaneously hypertensive rats through GLP-1 signaling \[[@B15]\].

In our research, the expression of*Angptl3* was downregulated in vildagliptin-treated rats.*Angptl3* is a key regulator, which can inhibit lipoprotein lipase (LPL) activity \[[@B16], [@B17]\]. The enzyme LPL hydrolyzes TG to free fatty acids (FFA). ANGPTL3 overexpression mice had high plasma TG levels \[[@B18]\]. Patients with a loss-of-function mutation of*Angptl3* are characterized by low plasma TC, TG, HDL-C, and LDL-C \[[@B19], [@B20]\]. In 2008, Kathiresan et al. first identified an SNP site near ANGPTL3 that was associated with plasma TG levels in a genome-wide association study \[[@B21]\]. In obesity and T2D subjects, the ANGPTL3 level was higher than that in healthy subjects \[[@B22]\]. Moreover, the level of ANGPTL3 was increased in the livers of insulin-deficient and insulin-resistant diabetic mice \[[@B23]\]. In mice and monkeys, using ANGPTL3-specific antibodies led to reduced plasma TG \[[@B24]--[@B26]\]. The therapeutic targets of the inhibition activity of ANGPTL require further research to treat dyslipidemia \[[@B16], [@B17]\].

We also found that the expression of*Bhmt* was reduced in the vildagliptin-treated group. Methionine (Met) was produced from methylate homocysteine (Hcy) by BHMT enzymes with betaine. Thus, BHMT can reduce Hcy levels and increase Met levels. Met can then be converted to S-adenosylmethionine (SAM).*In vivo*, SAM is a main methyl donor to regulate methionine metabolism in many reactions. An increase in BHMT activity and SAM levels was observed in the livers of both type 1 diabetic rats \[[@B27]\] and the type 2 diabetic model \[[@B28], [@B29]\]. Insulin treatment in the rat hepatoma cell line and STZ-induced diabetic rats can inhibit the excess expression of BHMT and SAM \[[@B28], [@B30]\].

Moreover, our results showed that Pon1 was upregulated in the vildagliptin-treated group. Pon1 is an enzyme that has antioxidant functions. In serum, Pon1 is located in HDL. Pon1 protects LDL from oxidation and hydrolyzed oxidized LDL \[[@B31]--[@B34]\]. HDL levels are negatively associated with the risk of developing coronary artery disease (CAD), but high levels of oxidized LDL (oxLDL) in the aorta lead to cholesterol accumulation, foam cell formation, and atherosclerotic lesions \[[@B31], [@B35]\]. Low Pon1 expression accelerates aortic lesion development in mice \[[@B36]\]. In humans, serum PON level is reduced in patients with a history of myocardial infarction \[[@B32]\] and diabetic patients \[[@B37]\]. PON1 transgenic mice had decreased oxidative stress and atherosclerotic lesions \[[@B38], [@B39]\], whereas PON1 knockout mice had increased serum oxidative stress and were more susceptible to high-fat-diet-induced atherosclerosis \[[@B34], [@B40]\].

5. Conclusion {#sec5}
=============

In conclusion, this study has confirmed that vildagliptin significantly attenuates endothelial dysfunction in diabetic rats. Importantly, our study indicates that vildagliptin may activate*Pon1* expression and inhibit the expression of*Bhmt* and*Angptl3* in the aorta. This study may increase the understanding of the pathways that contribute to which DPP-4 inhibitor attenuates endothelial dysfunction. More studies are needed to investigate whether or not vildagliptin treatment directly alters*Agptl3*,*Bhmt*, and*Pon1* expression in the aorta of diabetic rats, independent of blood glucose ([Figure 5](#fig5){ref-type="fig"}).
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![Effect of vildagliptin on metabolic parameters in rats. (a) Body weight, (b) fasting blood glucose, (c) insulin, (d) homeostasis model assessment (HOMA-IR), (e) blood glucose in oral glucose tolerance test (OGTT), (f) area under the curve (AUC) in OGTT, (g) total cholesterol, (h) triglyceride, (i) high-density lipoprotein cholesterol (HDL-C), (j) low-density lipoprotein cholesterol (LDL-C), and (k) relaxation responses to Ach in aortic rings. Values are mean ± SD (*n* = 6), ^*∗*^*P* \< 0.05, ^*∗∗*^*P* \< 0.01, versus control group; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus diabetic group. vil-low: low dose of vildagliptin; vil-high: high dose of vildagliptin.](BMRI2018-3109251.001){#fig1}

![Enriched biological process for the differentially expressed genes between vil-high group and diabetic group.](BMRI2018-3109251.002){#fig2}

![Interaction of differentially expressed genes between vil-high group and diabetic group from String software.*Angptl3*,*Bhmt*, and*Pon1* are circled in red.](BMRI2018-3109251.003){#fig3}

![Confirmation of three representative differentially expressed genes by qPCR. Values are mean ± SD (*n* = 6).*Angptl3*: angiopoietin-like 3;*Bhmt*: betaine-homocysteine S-methyltransferase;*Pon1*: paraoxonase 1. ^*∗∗*^*P* \< 0.01 versus control group; ^\#\#^*P* \< 0.01 versus diabetic group. vil-low: low dose of vildagliptin; vil-high: high dose of vildagliptin.](BMRI2018-3109251.004){#fig4}

![*The possible mechanism of attenuation of vildagliptin on endothelial dysfunction*. Vildagliptin attenuates endothelial dysfunction in diabetic rats through activating*Pon1* expression in aorta to inhibit oxLDL production; inhibiting Bhmt expression to reduce Met and SAM production; inhibiting*Angptl3* expression to activate LPL activity and thereby reduce plasma TG level. LDL: low-density lipoprotein; Pon1: paraoxonase 1; oxLDL: oxidized low-density lipoprotein; Hcy: homocysteine; Bhmt: betaine-homocysteine S-methyltransferase; Met: methionine, SAM: S-adenosylmethionine; TG: triglyceride.](BMRI2018-3109251.005){#fig5}

###### 

Oligonucleotide sequences for qPCR analysis.

  Gene symbol   GenBank ID     Forward primer          Reverse Primer         Product size
  ------------- -------------- ----------------------- ---------------------- --------------
  *Angptl3*     NM_001025065   AAAGGGTTTTGGGAGGCTTGA   CCCAAAAGCGCTATGGTCTC   117
  *Bhmt*        NM_030850      GATGCTTGGGGAGTGACGAA    TGTGGCTACTGTGCGGATTT   119
  *Pon1*        NM_032077      AAGCTGGCTACACCCACATC    CAACATTCGTTGGTGAGCGG   103

*Angptl3*: angiopoietin-like 3; *Bhmt*: betaine-homocysteine S-methyltransferase; *Pon1*: paraoxonase 1.

###### 

The enriched GO terms with differentially expressed genes (*P* \< 0.05).

  Term ID      Term name                                                                                                                                                                                           Count   *P*-value        Fold Enrichment   catalogue             Genes
  ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ---------------- ----------------- --------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0010951   negative regulation of endopeptidase activity                                                                                                                                                       16      7.22 × 10^−10^   8.425             Biology Process       KNG1, MUG2, MUG1, SERPINA10, PZP, C5, AHSG, AMBP, SERPINA3N, SERPINF2, SERPINA4, SERPINC1, ITIH4, HRG, ITIH2, SERPIND1
  GO:0019373   epoxygenase P450 pathway                                                                                                                                                                            7       5.88 × 10^−7^    21.821            Biology Process       CYP2C6V1, CYP2B3, CYP2J4, CYP2C23, CYP2C13, CYP2A1, CYP2A2
  GO:0006953   acute-phase response                                                                                                                                                                                7       7.97 × 10^−6^    14.356            Biology Process       KNG1, MUG1, CRP, ITIH4, SAA4, SERPINA1, AHSG
  GO:0007596   blood coagulation                                                                                                                                                                                   8       2.08 × 10^−5^    9.446             Biology Process       F13B, F12, SERPINA10, C9, F9, SERPIND1, CPB2, PLG
  GO:0055114   oxidation-reduction process                                                                                                                                                                         23      3.29 × 10^−5^    2.753             Biology Process       ALDH8A1, CYP2B3, CYP2J4, HSD3B5, DECR2, RGD1304810, CYP2D3, EGLN1, KMO, P4HTM, VAT1, IYD, CYP2C6V1, TDO2, CYP3A23/3A1, HIF1AN, CYP4F4, CYP2C23, CYP2C13, SH3BGRL3, RDH16, CYP2A1, CYP2A2
  GO:0007010   cytoskeleton organization                                                                                                                                                                           10      3.95 × 10^−5^    6.089             Biology Process       CCL24, TNIK, CAP2, TUBB2A, SVIL, CAMSAP1, STRIP2, TUBB6, TUBA1A, TUBB4B
  GO:0051918   negative regulation of fibrinolysis                                                                                                                                                                 4       6.93 × 10^−5^    44.533            Biology Process       SERPINF2, HRG, CPB2, PLG
  GO:0007017   microtubule-based process                                                                                                                                                                           6       1.68 × 10^−4^    11.405            Biology Process       TUBB2A, TUBB5, TUBB6, TUBA1A, DCTN1, TUBB4B
  GO:0046470   phosphatidylcholine metabolic process                                                                                                                                                               4       6.75 × 10^−4^    22.267            Biology Process       APOA5, PON1, GPLD1, LIPC
  GO:0042730   fibrinolysis                                                                                                                                                                                        4       8.35 × 10^−4^    20.782            Biology Process       F12, HRG, CPB2, PLG
  GO:0031100   organ regeneration                                                                                                                                                                                  7       0.00110          5.995             Biology Process       APOA2, BAAT, ADH1, ALDOC, APOA5, PRPS2, AHSG
  GO:0006958   complement activation, classical pathway                                                                                                                                                            5       0.00123          10.532            Biology Process       C9, C5, CRP, C4BPB, C4BPA
  GO:0006954   inflammatory response                                                                                                                                                                               12      0.00158          3.149             Biology Process       CCL24, KNG1, TLR10, SERPINA3N, TNFRSF10B, MUG1, CCL21, C5, HRH4, CCL9, SERPINA1, CXCR3
  GO:0050996   positive regulation of lipid catabolic process                                                                                                                                                      3       0.00236          38.967            Biology Process       APOA2, APOA5, ANGPTL3
  GO:0070328   triglyceride homeostasis                                                                                                                                                                            4       0.00431          11.990            Biology Process       APOC4, APOA5, LIPC, ANGPTL3
  GO:0007568   aging                                                                                                                                                                                               11      0.00745          2.721             Biology Process       ADRB3, CYP3A23/3A1, CRYAB, ENDOG, ALDOC, CRP, SPINK1, IGFBP1, ATP5G3, SREBF2, HTR2A
  GO:0071346   cellular response to interferon-gamma                                                                                                                                                               5       0.00766          6.388             Biology Process       CCL24, SERPINA3N, CCL21, CCL9, CFH
  GO:0008203   cholesterol metabolic process                                                                                                                                                                       5       0.00811          6.285             Biology Process       APOA2, PON1, LIPC, ANGPTL3, SREBF2
  GO:0042632   cholesterol homeostasis                                                                                                                                                                             5       0.00906          6.089             Biology Process       CAV3, APOA2, APOA5, LIPC, ANGPTL3
  GO:0042246   tissue regeneration                                                                                                                                                                                 4       0.00996          8.907             Biology Process       SERPINA10, APOA5, IGFBP1, PLG
  GO:0046330   positive regulation of JNK cascade                                                                                                                                                                  5       0.0112           5.730             Biology Process       DIXDC1, CCL21, SERPINF2, MAP3K10, TPD52L1
  GO:0050921   positive regulation of chemotaxis                                                                                                                                                                   3       0.0134           16.700            Biology Process       CCL21, C5, CXCR3
  GO:0006956   complement activation                                                                                                                                                                               3       0.0153           15.587            Biology Process       C8A, C5, CFH
  GO:2000649   regulation of sodium ion transmembrane transporter activity                                                                                                                                         3       0.0153           15.587            Biology Process       CAV3, SCN1B, SCN2B
  GO:0042573   retinoic acid metabolic process                                                                                                                                                                     3       0.0173           14.613            Biology Process       ALDH8A1, ADH1, RDH16
  GO:0009395   phospholipid catabolic process                                                                                                                                                                      3       0.0217           12.989            Biology Process       APOA2, ENPP2, ANGPTL3
  GO:0001666   response to hypoxia                                                                                                                                                                                 9       0.0230           2.598             Biology Process       CRYAB, ANG, CAMK2G, ALDOC, CRP, SERPINA1, EGLN1, PAK1, LIPC
  GO:0055117   regulation of cardiac muscle contraction                                                                                                                                                            3       0.0241           12.305            Biology Process       CAV3, P2RX4, CALM3
  GO:0055090   acylglycerol homeostasis                                                                                                                                                                            2       0.0254           77.933            Biology Process       APOA5, ANGPTL3
  GO:0034370   triglyceride-rich lipoprotein particle remodeling                                                                                                                                                   2       0.0254           77.933            Biology Process       APOA2, APOA5
  GO:0031116   positive regulation of microtubule polymerization                                                                                                                                                   3       0.0265           11.690            Biology Process       CAV3, MAP1B, DCTN1
  GO:0032956   regulation of actin cytoskeleton organization                                                                                                                                                       4       0.0287           5.995             Biology Process       DIXDC1, HRG, PAK1, SH3BGRL3
  GO:0048247   lymphocyte chemotaxis                                                                                                                                                                               3       0.0317           10.627            Biology Process       CCL24, CCL21, CCL9
  GO:0070098   chemokine-mediated signaling pathway                                                                                                                                                                4       0.0363           5.469             Biology Process       CCL24, CCL21, CCL9, CXCR3
  GO:0045959   negative regulation of complement activation, classical pathway                                                                                                                                     2       0.0378           51.956            Biology Process       C4BPB, C4BPA
  GO:0002542   Factor XII activation                                                                                                                                                                               2       0.0378           51.956            Biology Process       KNG1, F12
  GO:0009725   response to hormone                                                                                                                                                                                 5       0.0381           3.936             Biology Process       ANG, APOA5, LIPC, ANGPTL3, SREBF2
  GO:0042311   vasodilation                                                                                                                                                                                        3       0.0402           9.352             Biology Process       KNG1, P2RX4, ALB
  GO:0006631   fatty acid metabolic process                                                                                                                                                                        4       0.0413           5.196             Biology Process       BAAT, DECR2, LIPC, ANGPTL3
  GO:0007399   nervous system development                                                                                                                                                                          7       0.0428           2.741             Biology Process       PLXNA4, SCN2B, CAMK2G, KREMEN1, MAP1B, DPYSL3, NUMBL
  GO:0048675   axon extension                                                                                                                                                                                      3       0.0431           8.992             Biology Process       SEMA7A, MAP1B, POU4F3
  GO:0072659   protein localization to plasma membrane                                                                                                                                                             4       0.0485           4.871             Biology Process       CAV3, TNIK, FGF13, CDH1
  GO:0006935   chemotaxis                                                                                                                                                                                          4       0.0485           4.871             Biology Process       CCL24, ENPP2, C5, CXCR3
  GO:0006810   transport                                                                                                                                                                                           6       0.0489           3.017             Biology Process       P2RX4, DYNC1LI1, AFM, LOC360919, ALB, LOC500473
  GO:0072562   blood microparticle                                                                                                                                                                                 22      1.84 × 10^−18^   14.631            Cellular Components   KNG1, GC, C9, MUG1, APCS, C4BPA, PLG, AHSG, C8A, AMBP, APOA2, AFM, SERPINF2, ALB, HPX, APOA5, PON1, CFH, SERPINC1, ITIH4, HRG, ITIH2
  GO:0005615   extracellular space                                                                                                                                                                                 49      2.19 × 10^−11^   2.922             Cellular Components   MUG2, MUG1, PZP, CRP, GPLD1, SPINK1, ANPEP, AZGP1, APOA2, ANG, SEMA7A, SERPINA4, APOA5, CFH, SERPINA1, SEMA3B, KNG1, F12, APCS, LOC360919, F9, C8A, AMBP, SERPINA3N, SERPINF2, SCGB2A2, GC, SERPINA10, ENPP2, C5, CCL9, AHSG, CCL24, ALB, CCL21, SERPINC1, ANGPTL3, C4BPB, DPYSL3, C4BPA, PLG, AFM, HPX, PON1, METRNL, SERPIND1, IGFBP1, LIPC, CPB2
  GO:0034364   high-density lipoprotein particle                                                                                                                                                                   7       4.31 × 10^−8^    32.313            Cellular Components   APOA2, APOC4, APOA5, PON1, GPLD1, SAA4, LIPC
  GO:0070062   extracellular exosome                                                                                                                                                                               66      6.06 × 10^−8^    1.957             Cellular Components   ALDH8A1, CYP2J4, MUG1, TUBB2A, CRP, GPLD1, ANPEP, CKB, AZGP1, APOA2, DES, PACSIN3, ANG, SERPINA4, ITIH4, TUBB5, CFH, TUBB6, ITIH2, SEMA3B, SERPINA1, TUBA1A, KNG1, F12, TNIK, APCS, CRYAB, F9, METTL7A, VAT1, AMBP, C8A, RPS16, SERPINF2, BHMT, PRNP, SLC27A2, PRPS2, GC, C9, SERPINA10, ALDOC, C5, CDH1, KMO, AHSG, ALCAM, ALB, SERPINC1, DOPEY2, HRG, TUBB4B, COTL1, PLG, P2RX4, AFM, HPX, ARF3, PON1, CALM3, PAPPA2, METRNL, SERPIND1, SH3BGRL3, MYH14, CPB2
  GO:0031090   organelle membrane                                                                                                                                                                                  11      2.10 × 10^−7^    9.591             Cellular Components   CYP2C6V1, CYP2B3, UGT2B37, UGT2B17, CYP3A23/3A1, CYP4F4, CYP2C23, CYP2D3, CYP2C13, CYP2A1, CYP2A2
  GO:0030018   Z disc                                                                                                                                                                                              9       1.24 × 10^−4^    6.037             Cellular Components   CAV3, JPH2, DES, CRYAB, BAG3, PDLIM3, PAK1, HOMER1, FLNC
  GO:0014704   intercalated disc                                                                                                                                                                                   6       4.60 × 10^−4^    9.232             Cellular Components   CAV3, SCN1B, DES, ATP2A2, FGF13, PAK1
  GO:0030426   growth cone                                                                                                                                                                                         9       6.13 × 10^−4^    4.772             Cellular Components   ANG, CRP, MAP1B, CALM3, DPYSL3, FGF13, MYH14, PAK1, HAP1
  GO:0005874   microtubule                                                                                                                                                                                         11      8.97 × 10^−4^    3.658             Cellular Components   DYNC1LI1, TUBB2A, CAMSAP1, MAP1B, TUBB5, TUBB6, FGF13, TUBA1A, DCTN1, TUBB4B, GLYATL2
  GO:0043034   costamere                                                                                                                                                                                           4       0.00196          15.695            Cellular Components   SVIL, SYNM, HOMER1, FLNC
  GO:0005576   extracellular region                                                                                                                                                                                19      0.00456          2.088             Cellular Components   APCS, C9, CRP, NTN4, GPLD1, SAA4, C4BPB, FGF13, PTH2, C4BPA, PLG, LOC500473, CCL24, C8A, SERPINA3N, ALB, APOA5, HRG, LIPC
  GO:0005789   endoplasmic reticulum membrane                                                                                                                                                                      16      0.00504          2.258             Cellular Components   CYP2B3, CDIPT, HSD3B5, CYP2D3, SREBF2, CYP2C6V1, UGT2B37, UGT2B17, CYP3A23/3A1, ATP2A2, CYP4F4, CYP2C23, CYP2C13, CYP2A1, CYP2A2, SLC27A2
  GO:0030424   axon                                                                                                                                                                                                12      0.00657          2.609             Cellular Components   GC, ALCAM, P2RX4, CRYAB, ALDOC, MAP1B, FGF13, CDH1, MYH14, PAK1, HOMER1, HTR2A
  GO:0034361   very-low-density lipoprotein particle                                                                                                                                                               3       0.0192           13.848            Cellular Components   APOA2, APOC4, APOA5
  GO:0043231   intracellular membrane-bounded organelle                                                                                                                                                            16      0.0302           1.825             Cellular Components   KNG1, CYP2B3, CAV3, CYP2J4, HSD3B5, GPLD1, PLG, SREBF2, AMBP, UGT2B17, CYP3A23/3A1, PON1, CYP2C23, UGT2A3, CYP2A1, SLC27A2
  GO:0005856   cytoskeleton                                                                                                                                                                                        8       0.0345           2.605             Cellular Components   TNIK, DES, FILIP1, MAP1B, FLNC, COTL1, TPM2, HAP1
  GO:0044216   other organism cell                                                                                                                                                                                 2       0.0376           52.316            Cellular Components   C4BPB, C4BPA
  GO:0033017   sarcoplasmic reticulum membrane                                                                                                                                                                     3       0.0457           8.719             Cellular Components   JPH2, ATP2A2, CAMK2G
  GO:0004867   serine-type endopeptidase inhibitor activity                                                                                                                                                        15      6.34 × 10^−11^   11.167            Molecular Function    MUG2, PZP, MUG1, SERPINA10, SPINK1, AMBP, SERPINA3N, SERPINF2, SERPINA4, SERPINC1, ITIH4, HRG, ITIH2, SERPINA1, SERPIND1
  GO:0070330   aromatase activity                                                                                                                                                                                  9       2.65 × 10^−8^    18.039            Molecular Function    CYP2C6V1, CYP2B3, CYP3A23/3A1, CYP4F4, CYP2C23, CYP2D3, CYP2C13, CYP2A1, CYP2A2
  GO:0008392   arachidonic acid epoxygenase activity                                                                                                                                                               8       1.97 × 10^−7^    18.393            Molecular Function    CYP2C6V1, CYP2B3, CYP2J4, CYP2C23, CYP2D3, CYP2C13, CYP2A1, CYP2A2
  GO:0008395   steroid hydroxylase activity                                                                                                                                                                        8       5.35 × 10^−7^    16.035            Molecular Function    CYP2C6V1, CYP2B3, CYP2J4, CYP2C23, CYP2D3, CYP2C13, CYP2A1, CYP2A2
  GO:0020037   heme binding                                                                                                                                                                                        13      1.46 × 10^−6^    6.122             Molecular Function    CYP2B3, CYP2J4, CYP2D3, AMBP, CYP2C6V1, TDO2, CYP3A23/3A1, CYP4F4, CYP2C23, HRG, CYP2C13, CYP2A1, CYP2A2
  GO:0008092   cytoskeletal protein binding                                                                                                                                                                        8       1.07 × 10^−5^    10.423            Molecular Function    DES, PACSIN3, CRYAB, ALDOC, PDLIM3, CDH1, FLNC, ABCG2
  GO:0005506   iron ion binding                                                                                                                                                                                    13      1.11 × 10^−5^    5.031             Molecular Function    CYP2B3, CYP2J4, CYP2D3, EGLN1, P4HTM, CYP2C6V1, CYP3A23/3A1, HIF1AN, CYP4F4, CYP2C23, CYP2C13, CYP2A1, CYP2A2
  GO:0004866   endopeptidase inhibitor activity                                                                                                                                                                    5       5.40 × 10^−4^    13.028            Molecular Function    MUG2, MUG1, C5, SERPINA1, AHSG
  GO:0017080   sodium channel regulator activity                                                                                                                                                                   5       6.95 × 10^−4^    12.214            Molecular Function    CAV3, SCN1B, SCN2B, GPLD1, FGF13
  GO:0016712   oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen         5       8.78 × 10^−4^    11.495            Molecular Function    CYP2B3, CYP2J4, CYP3A23/3A1, CYP2D3, CYP2A1
  GO:0005200   structural constituent of cytoskeleton                                                                                                                                                              6       0.00223          6.514             Molecular Function    TUBB2A, TUBB5, TUBB6, SYNM, TUBA1A, TUBB4B
  GO:0016706   oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors   4       0.00262          14.213            Molecular Function    HIF1AN, RGD1304810, EGLN1, P4HTM
  GO:0008201   heparin binding                                                                                                                                                                                     8       0.00268          4.283             Molecular Function    SERPINA10, ANG, APOA5, SERPINC1, CFH, HRG, SERPIND1, LIPC
  GO:0016705   oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen                                                                                               5       0.00297          8.316             Molecular Function    CYP2C6V1, CYP2B3, CYP2C23, EGLN1, CYP2C13
  GO:0005102   receptor binding                                                                                                                                                                                    12      0.00666          2.598             Molecular Function    KNG1, HAO1, P2RX4, BAAT, ANG, LRRC4B, DECR2, HRG, HOMER1, SLC27A2, HAP1, PLG
  GO:0004497   monooxygenase activity                                                                                                                                                                              5       0.00944          6.013             Molecular Function    CYP2C6V1, CYP2B3, CYP2C23, CYP2D3, CYP2C13
  GO:0004622   lysophospholipase activity                                                                                                                                                                          3       0.01328          16.751            Molecular Function    ENPP2, LIPC, GDPD1
  GO:0042803   protein homodimerization activity                                                                                                                                                                   19      0.01474          1.845             Molecular Function    RBPMS2, CRYAB, GIMAP7, CAMK2G, CRP, NR4A1, TPD52L1, ABCG2, AMBP, ADRB3, APOA2, HIF1AN, ANG, SERPINF2, ADH1, TENM3, PON1, RDH16, PRPS2
  GO:0005543   phospholipid binding                                                                                                                                                                                5       0.0198           4.825             Molecular Function    APOA2, APOA5, MAP1B, PON1, SYTL3
  GO:0044325   ion channel binding                                                                                                                                                                                 6       0.0233           3.693             Molecular Function    CAV3, CALM3, FGF13, PRNP, HOMER1, HAP1
  GO:0048020   CCR chemokine receptor binding                                                                                                                                                                      3       0.0239           12.342            Molecular Function    CCL24, CCL21, CCL9
  GO:0043395   heparan sulfate proteoglycan binding                                                                                                                                                                3       0.0289           11.167            Molecular Function    CFH, HRG, LIPC
  GO:0030215   semaphorin receptor binding                                                                                                                                                                         3       0.0289           11.167            Molecular Function    SEMA7A, SEMA3B, SH3BGRL3
  GO:0005509   calcium ion binding                                                                                                                                                                                 16      0.0330           1.797             Molecular Function    MATN2, F12, APCS, CALR4, TBC1D9, ENPP2, CRP, DECR2, F9, CDH1, P4HTM, ATP2A2, PON1, ITIH4, CALM3, SYTL3
  GO:0008307   structural constituent of muscle                                                                                                                                                                    3       0.0371           9.771             Molecular Function    PDLIM3, SYNM, TPM2
  GO:0003779   actin binding                                                                                                                                                                                       8       0.0406           2.511             Molecular Function    GC, DIXDC1, CAP2, ANG, DIAPH3, MAP1B, COTL1, TPM2
  GO:0015020   glucuronosyltransferase activity                                                                                                                                                                    3       0.0460           8.685             Molecular Function    UGT2B37, UGT2B17, UGT2A3
  GO:0005507   copper ion binding                                                                                                                                                                                  4       0.0463           4.963             Molecular Function    P2RX4, ANG, PRNP, ATP7B
  GO:0005515   protein binding                                                                                                                                                                                     29      0.0484           1.427             Molecular Function    CAV3, GC, SCN1B, ALDOC, CRP, CDH1, RHOV, CKB, A1CF, TUBB5, SERPINC1, SERPINA1, PAK1, TUBA1A, HAP1, TUBB4B, SCN2B, CRYAB, MAP1B, HRK, NR4A1, HOMER1, NUMBL, P2RX4, ATP2A2, CALM3, SLC27A2, PRPS2, HTR2A

###### 

The enriched Kegg pathway with differentially expressed genes (*P* \< 0.05).

  Pathway ID   Pathway name                                       Count   *P*-value        Fold Enrichment   Genes
  ------------ -------------------------------------------------- ------- ---------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  rno04610     Complement and coagulation cascades                16      7.92 × 10^−14^   14.904            KNG1, F12, C9, C5, F9, C4BPB, C4BPA, PLG, F13B, C8A, SERPINF2, CFH, SERPINC1, SERPINA1, SERPIND1, CPB2
  rno00830     Retinol metabolism                                 12      3.00 × 10^−8^    9.697             CYP2C6V1, CYP2B3, UGT2B37, UGT2B17, CYP3A23/3A1, ADH1, CYP2C23, CYP2C13, UGT2A3, CYP2A1, RDH16, CYP2A2
  rno00140     Steroid hormone biosynthesis                       10      2.63 × 10^−6^    8.280             CYP2C6V1, CYP2B3, UGT2B37, UGT2B17, CYP3A23/3A1, HSD3B5, CYP2C23, CYP2D3, CYP2C13, UGT2A3
  rno05204     Chemical carcinogenesis                            9       5.47 × 10^−5^    6.633             CYP2C6V1, CYP2B3, UGT2B37, UGT2B17, CYP3A23/3A1, ADH1, CYP2C23, CYP2C13, UGT2A3
  rno00591     Linoleic acid metabolism                           5       3.01 × 10^−3^    8.179             CYP2C6V1, CYP2J4, CYP3A23/3A1, CYP2C23, CYP2C13
  rno04750     Inflammatory mediator regulation of TRP channels   7       6.98 × 10^−3^    4.082             CYP2C6V1, CYP2J4, CAMK2G, CYP2C23, CALM3, CYP2C13, HTR2A
  rno04540     Gap junction                                       6       9.57 × 10^−3^    4.573             TUBB2A, TUBB5, TUBB6, TUBA1A, TUBB4B, HTR2A
  rno05020     Prion diseases                                     4       1.14 × 10^−2^    8.384             C8A, C9, C5, PRNP
  rno01100     Metabolic pathways                                 30      1.17 × 10^−2^    1.556             CYP2B3, CYP2J4, PGS1, CDIPT, TUSC3, ALDOC, HSD3B5, KMO, ANPEP, ATP5G3, CKB, TDO2, ADH1, CYP2C13, UGT2A3, CYP2C6V1, MAN2A2, HAO1, UGT2B37, UGT2B17, BAAT, CYP3A23/3A1, BHMT, PON1, CYP2C23, LIPC, RDH16, CYP2A1, CYP2A2, PRPS2
  rno00590     Arachidonic acid metabolism                        5       3.16 × 10^−2^    4.140             CYP2C6V1, CYP2B3, CYP2J4, CYP2C23, CYP2C13
  rno04726     Serotonergic synapse                               6       3.63 × 10^−2^    3.245             CYP2C6V1, CYP2J4, CYP2C23, CYP2D3, CYP2C13, HTR2A
  rno04360     Axon guidance                                      6       4.08 × 10^−2^    3.144             PLXNA4, SEMA7A, NTN4, SEMA3B, PAK1, UNC5C

###### 

The top 10 genes from gene interaction analysis.

  Gene Accession       Gene Symbol   gene name                                                          degree
  -------------------- ------------- ------------------------------------------------------------------ --------
  NM_019369            Itih4         inter-alpha-trypsin inhibitor heavy chain family, member 4         17
  NM_053491            Plg           plasminogen                                                        16
  NM_001014006         F12           coagulation factor XII (Hageman factor)                            12
  NM_001012027         Serpinc1      serpin peptidase inhibitor, clade C (antithrombin), member 1       11
  NM_138514            Cyp2c13       cytochrome P450, family 2, subfamily c, polypeptide 13             9
  NM_019287            Apob          apolipoprotein B                                                   8
  ENSRNOT00000074103   Cyp2c6        cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1   8
  NM_053318            Hpx           hemopexin                                                          8
  NM_022519            Serpina1      clade A (alpha-1 antiproteinase, antitrypsin), member 1            8
  NM_001108802         Speg          SPEG complex locus                                                 7
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